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Summary
The expansion of adipose tissue (AT) in obesity is accompanied by the
accumulation of immune cells that contribute to a state of low-grade,
chronic inflammation and dysregulated metabolism. Adipose tissue
macrophages (ATMs) represent the most abundant class of leukocytes in
AT and are involved in the regulation of several regulatory physiological
processes, such as tissue remodeling and insulin sensitivity. With progres-
sive obesity, ATMs are key mediators of meta-inflammation, insulin resis-
tance and impairment of adipocyte function. While macrophage
recruitment from blood monocytes is a critical component of the genera-
tion of AT inflammation, new studies have revealed a role for ATM pro-
liferation in the early stages of obesity and in sustaining AT
inflammation. In addition, studies have revealed a more complex range of
macrophage activation states than the previous M1/M2 model, and the
existence of different macrophage profiles between human and animal
models. This review will summarize the current understanding of the reg-
ulatory mechanisms of ATM function in relation to obesity, type 2 dia-
betes, depot of origin, and to other leukocytes such as AT dendritic cells,
with hopes of emphasizing the regulatory nodes that can potentially be
targeted to prevent and treat obesity-related metabolic disorders.
Keywords: adipose tissue; inflammation; insulin resistance; macrophages;
MMe; obesity.
Introduction
The incidence of obesity and associated co-morbidities
[type 2 diabetes (DM), liver and cardiovascular diseases,
and certain forms of cancer] remains on the rise.1 Obesity
results from a chronic imbalance between caloric intake
and energy expenditure that is characterized as a low-
grade, chronic inflammatory disease that contributes to
metabolic dysfunction and insulin resistance (IR).2
Although the molecular basis underpinning this inflam-
mation is not fully understood, there is consensus that
macrophage activation in adipose tissue (AT) precedes
the development of IR and contributes to a pro-inflam-
matory state.3,4 Therefore, deciphering macrophage biol-
ogy and pathophysiology in the obese setting remains a
unique challenge to the field of immunology and metabo-
lism research. Transcriptional profiling has advanced the
understanding of the plasticity of macrophages suggesting
a complex cellular programming in response to stress sig-
nals,5 and has emphasized the concept that macrophages
can quickly adopt unique properties depending on micro-
environmental cues.6 Nevertheless, the mechanisms
underpinning the specialized transcriptional and signaling
profiles in macrophages during obesity-induced AT
inflammation are not fully resolved. In this review, we
will summarize what is known about adipose tissue
macrophage (ATM) biology in the setting of obesity and
metabolic disease in a rapidly moving field of
investigation.
ATM-driven inflammation links obesity to IR
Obesity is characterized by a chronic low-grade inflam-
mation that is causally implicated in the development of
IR. IR is a central mechanism in obesity-associated dis-
eases, such as DM and metabolic syndrome. It is defined
as the decline to a normal physiological response to insu-
lin, resulting in a reduction in glucose disposal as well as
failure to suppress lipolysis and hepatic glucose produc-
tion, and occurs prominently in AT. Numerous studies
support the role of ATMs and derived inflammatory
mediators in the impairment of insulin signaling
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pathways.7–10 ATM-derived pro-inflammatory cytokines
inhibit insulin action via activating pro-inflammatory
kinases, including IkB kinase (IKK) and JNK in adipo-
cytes.11 Ablation of JNK in macrophages protects mice
from obesity-induced IR by reducing macrophages infil-
tration into pancreatic islets and blocking ATM polariza-
tion toward an inflammatory phenotype.12 Insulin binds
to its receptor, the insulin receptor ‘IR’ and its homolo-
gous insulin-like growth factor 1 receptor ‘IGFR’, on
macrophages to induce a signaling cascade that leads to a
metabolic reprograming to promote activation.13 It was
demonstrated that IGFR1 signal transduction promotes
alternative macrophage polarization, as well as the lack of
IGFR1 results in a higher pro- versus anti-inflammatory
ATM ratio, less phagocytosis and more infiltration into
AT.14 Studies in IRΔmyel-mice bearing the conditional
inactivation of the insulin receptor in myeloid lineage
cells have also demonstrated that these mice remain pro-
tected from the development of obesity-associated IR and
exhibit a decreased chronic, low-grade inflammatory
state.15 These findings clearly point out that insulin action
plays a key role in regulating macrophage biology in AT
during obesity-driven IR and inflammation.15
ATM activation states
Adipose tissue macrophages in lean and obese/insulin-
resistant settings were initially described based on the
two-dimensional M1/M2 spectrum of macrophage activa-
tion16 (Fig. 1). While this paradigm was a useful model
initially, advances in the understanding of a spectrum of
macrophage activation have challenged the accuracy of
this model and its application to in vivo ATM popula-
tions.17–19 Evidence has suggested that obesity-associated
ATMs include highly plastic cell populations, whose
immuno-phenotype is determined in response to multiple
stimuli in their surrounding microenvironment. It is now
evident that more than one population of ATMs exist in
obese AT,20 and these distinct populations express specific
markers, have unique tissue distributions, transcriptional
profiles and functions. The exact number and functions
of ATM subsets in obese AT is evolving, and the tran-
scriptional mechanisms that define their unique activation
states are not fully known. In obesity, ATMs adopt a
metabolic activation state with prominent lysosomal
activity,17,18 with the main purpose to clear dead adipo-
cytes.19 Obese ATMs display surface markers that resem-
ble neither classical (M1) nor alternative (M2) activation,
but rather a state of metabolic activation (MMe) induced
by diverse metabolic stimuli (e.g. free fatty acids, high
insulin, high glucose)17 (Fig. 1). These views will be
informed by our understanding of the complexity of
macrophage activation.5 Stimulation of macrophages with
many different effectors, including pattern recognition
receptor ligands, cytokines and metabolic cues (e.g. free
fatty acids, high-density lipoproteins) generates multiple
clusters of activation states,5 and thus may expand and
extend the current models.
ATM heterogeneity in mice
Adipose tissue macrophage diversity and heterogeneity
can be seen not only between lean and obese states, but
also based on the location of the AT depot (e.g. visceral
and subcutaneous AT), and also if the depot is composed
of white, brown or beige adipocytes. In all depots, ATMs
have been classified into two major subtypes: tissue-resi-
dent and monocyte-derived ‘recruited’ macrophages.
Number, localization and properties of ATMs greatly dif-
fer depending on the metabolic status.3,4 Numerically the
population of ATMs expands from 10% of all cells in
lean AT to more than 50% in severe obesity in mice.3,21
The increased number of ATMs in obese AT is due to
two distinct processes: recruitment of macrophages from
monocyte trafficking; and local proliferation of recruited
macrophages.
In lean mice, a resident ATM pool originates from
yolk-sac progenitors and self-renews by proliferation
under homeostatic conditions.22,23 Over time, these resi-
dent ATMs appear to be replaced with bone marrow-
derived macrophages, likely from monocyte intermedi-
ates.24 Mouse monocyte subsets are classified as Ly6C+
(further divided as Ly6Chigh and Ly6Cmiddle) and Ly6C
(also called Ly6Clow).25 Based on the expression of surface
markers and chemokine receptors, Ly6C+ subsets are
divided into: CD11b+ CD115+ and CCR2high CX3CR1low.
Ly6C monocytes are grouped as CD11b+ CD115+ and
CCR2low CX3CR1high.27 In steady-state, Ly6C+ monocytes
differentiate into Ly6C monocytes in the circulation. In
obese AT in response to inflammatory signals and
chemokines such as CCL2, Ly6C+ activated monocytes
migrate to the site of inflammation where they differenti-
ate into ATMs26,27 (Fig. 2). CCR2high Ly6C+ inflamma-
tory and CCR2low Ly6C resident monocytes are
generally thought to preferentially differentiate into M1
inflammatory and M2 anti-inflammatory macrophages,
respectively.25
Resident ATMs are distributed between adipocytes and
along vascular structures in AT, and are F4/
80+ CD64+ CD206+ CD301+ CD11c (Table 1). These
cells express anti-inflammatory molecules, regulate adipo-
cyte lipid metabolism by secreting factors such as IL-10
and catecholamines, and act as efferocytes to clear apop-
totic cells and resolve inflammation. With increased lipol-
ysis, resident macrophages contribute to lipid buffering
via the control of free fatty acids release into the circula-
tion. In the obese setting, these cells undergo a polariza-
tion shift toward a pro-inflammatory phenotype,28 as well
as alterations in death pathways leading to increased cell
survival.29
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A major stimulus for this recruitment is adipocyte
stress as ATMs accumulate around dead adipocytes form-
ing clusters called crown-like structures (CLSs).30
Recruited ATMs have been distinguished from the resi-
dent pool based on their localization to CLSs, as well as
their expression of CD11c, CCR2 and TLR428,31,32
(Table 1). CD11c has been a useful marker in both
mouse and human studies to differentiate pro-inflamma-
tory ATMs from the resident pool.21,33 Genetic ablation
of CD11c expressing ATMs can attenuate obesity-induced
inflammation and metabolic dysfunction.34 In conjunc-
tion with infiltrating cells from the periphery, there is evi-
dence indicating that local proliferation contributes to
increasing ATM number, and this phenomenon occurs
predominantly within the CLSs.35–37 In addition to
increased recruitment, proliferation and diminished
egress, increased cell longevity is an additional mechanism
by which ATM number is modulated in obese AT.29
Figure 1. Adipose tissue macrophages (ATMs) classification. ‘M0’ macrophages originate from bone marrow-derived monocytes or yolk-sac pro-
genitors. Depending on the stimuli, studies in mice have demonstrated that ‘M0’ macrophages differentiate into several subsets. Based on in vitro
experiments, ‘M1’ or ‘classical activated’ macrophages (CAMs) originate from the stimulation with lipopolysaccharide (LPS), interferon (IFN)-c
or tumor necrosis factor a (TNF-a). These macrophages are characterized by an IL-12high, IL-23high and IL-10low phenotype, display the surface
marker CD11c in addition to F4/80 and CD11b, and produce pro-inflammatory mediators like TNF-a, IL-6, IL-1b and nitric oxide (NO). ‘M2’
or ‘alternatively activated’ macrophages (AAMs) are macrophages with an anti-inflammatory phenotype derived from IL-4, IL-10, IL-13 and glu-
cocorticoids stimulation. M2 macrophages exhibit an IL-10high, IL-12low and IL-23low phenotype, express the cell-surface markers CD11b, F4/80,
CD301 and CD206, and secrete IL-4, IL-10 and IL-1 receptor antagonist (IL-1Ra). ‘M2’ macrophages are further divided into three major vari-
ants: ‘M2a’, elicited by type II cytokines IL-4 or IL-13; ‘M2b’, obtained by triggering of Fc gamma receptors in the presence of a Toll receptor
stimulus; and ‘M2c’, elicited by glucocortocoids, IL-10 or TGF-b. In obese setting, metabolic cues (e.g. free fatty acids, high insulin, high glucose,
oxidized phospholipids, oxidized LDL) give rise to a population of metabolic activated (MMe) or oxidized (Mox) macrophages associated to an
insulin-resistant state. For instance, saturated fatty acids, which are released from hypertrophied adipocytes during the course of obesity, can act
as a danger signal to MMe macrophages via the TLR4 complex. MMe macrophages exhibit a phenotype strikingly different from the typical M1/
M2. Cell-surface proteins specifically overexpressed by MMe macrophages include ABCA1, CD36 and PLIN2, while conventional M1/M2 markers
are suppressed. Mox macrophages are characterized by high expression of heme oxygenase-1 (HO-1), sulforedoxin-1 (Srnx-1), thioredoxin-1
reductase (Txnrd-1), all redox-regulatory genes under the control of the Nrf2 transcription factor, IL-10 and VEGF.
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Despite a broad use of CD11c as an inflammatory
ATM marker in human and mouse studies, there may be
limitations to the classification scheme using CD11c. Due
to its expression on dendritic cells (DCs), a question in
the field has been the ability to differentiate ATMs from
adipose tissue dendritic cells (ATDCs) given that F4/80
and CD11b are also found on ATDCs. Using macro-
phage-specific markers CD64 and MerTK,38 the popula-
tion of CD64 CD11c+ ATDCs is identifiable and distinct
from CD64+ CD11c+ and CD64+ CD11c ATM pools.39
While a CD11c-based scheme differentiates ATM subsets
in mice and humans, recent transcriptomic studies sug-
gest a revision to this scheme.39 Single-cell RNA sequenc-
ing and clustering analysis in murine samples suggested
that three main ATM populations can be identified by
the markers CD9 and Ly6C:40 Ly6c+; Ly6c CD9+; and
Ly6c CD9. The Ly6c+ identified recruited ATMs with
an adipogenic role that resided outside of CLSs, whose
adoptive transfer into lean mice was reported to activate
gene programs typical of normal adipocyte physiology.
The Ly6c CD9 expressed high levels of Mrc1/Cd206,
and were found in lean and obese settings consistent with
the previous definitions of resident ATMs. The
Ly6c CD9+ population was described as the subset that
accumulated with obesity specifically within the CLSs,
had high amounts of intracellular lipid in lysosome-like
structures, expressed genes related to lysosomal-depen-
dent lipid metabolism, secreted exosome-size vesicles, and
had gene expression and regulatory profiles enriched for
pro-inflammatory genes.40 Thus far, Ly6c+ (recruited sub-
set), Ly6c CD9+ (pro-inflammatory subset) and
Ly6c CD9 (anti-inflammatory subset) shared distinct
tissue localization, and Ly6c CD9+ were also identified
in human AT. The authors note a lack of differential
expression of CD11c in these populations, so future stud-
ies will need to clarify the functional role of CD9 in
ATMs as well as other AT stromal cells. CD9high adipo-
cyte progenitors41 have been identified as correlating with
AT fibrosis in humans, and CD9 is also found on DCs42
to control antigen presentation, suggesting a potential
broader role for CD9 in AT biology that has yet to be
understood.
Human ATM markers
In parallel with an increase in ATMs during obesity in
mice, macrophage numbers increase in AT in obese
humans, with the percentage of ATMs rising from 5%–
10% in the lean healthy status to 40%–50% of the stro-
mal cells in the obese setting.3,43 Similar to mice, there is
evidence suggesting the coexistence of diverse ATM popu-
lation subtypes that shape obesity-induced inflammation
in humans. In contrast to the pro-inflammatory pheno-
type switch of macrophages found in many mouse stud-
ies, flow cytometry analysis of human fat has suggested
that this phenomenon is fundamentally different in
human ATMs in obese individuals, and that ATMs are
better represented by a mixed inflammatory phenotype.
This mixed phenotype is characterized by the simultane-
ous presence of markers that generally belong to M2- and
M1-type macrophages,44 such as CD206 and CD11c. Fur-
ther ATM heterogeneity is seen when comparing different
fat depots (visceral versus subcutaneous) in humans.45
Human ATMs are generated from peripheral blood
monocytes that are divided into three subsets: classical
monocytes (CD14++ CD16); intermediate monocytes
(CD14++ CD16+); and non-classical monocytes
(CD14+ CD16++).25 It was suggested that CD14++ CD16
and CD14++ CD16+ monocytes resemble mouse Ly6C+
inflammatory monocyte subset, whereas CD14+ CD16++
Figure 2. Obesity-driven changes in adipose tissue-associated macrophages (ATMs). In lean adipose tissue (AT), eosinophils and type 2 innate
lymphoid cells (ILC2s) constitutively produce Th2 cytokines interleukin-4 (Il-4) and interleukin-13 (Il-13), respectively, which promote anti-in-
flammatory polarization of macrophages. As adiposity increases, obese AT manifests adipocyte hypertrophy, which leads to hypoxia, endoplasmic
reticulum stress and lipotoxicity resulting in excessive leptin, cytokine and chemokine secretion. Among others, monocyte chemotactic protein-1
(Mcp-1) induces Ly6C+ monocytes recruitment giving rise to tissue macrophages. Recruited macrophages, increased in number due to aug-
mented infiltration and local proliferation, undergo a drastic change in distribution, forming crown-like structures (CLSs) around dead adipo-
cytes. Additionally, they adopt a differential spectrum of functional properties and transcriptomic programming more prone to inflammation
and metabolic dysregulation. This includes increased production of pro-inflammatory cytokines and other secretory products.
Table 1. Markers for identification of ATMs
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monocytes resemble Ly6C anti-inflammatory monocytes
and have a patrolling role.25
In lean states, human ATMs are CD16 and express
markers CD14, CD68, CD163, CD204, CD206 analogous
to the population of ‘resident’ or anti-inflammatory
ATMs seen in mice (Table 1). CD14+ CD16 CD163+
ATMs have been described as an anti-inflammatory sub-
set inversely correlated with high body mass index
(BMI).46 However, studies have suggested that the pres-
ence of these cellular markers may not be limited to ‘resi-
dent’ or anti-inflammatory macrophages. In fact, AT of
obese individuals has been shown to express many mark-
ers of M2 macrophages that correlate with ATMs with
the capacity of secreting pro-inflammatory cytokines,47
and correlated with increased BMI.44 In human obese
AT, pro-inflammatory ATMs have been described as
CD14- and CD16-positive cells that display high levels of
other markers, such as CD11c, CD64, CD40, CD86,
HLA-DR, TLR4 and CD36 (Table 1). Importantly,
human CLS ATMs have been characterized for having a
mixed M1/M2 phenotype,44 expressing the ‘M1-like’ mar-
ker CD11c and the ‘M2-like’ marker CD206 or CD163.
Using CD11c to identify pro-inflammatory ATMs,48
the subset of CD11c+ CD206+ ATMs was shown to exhi-
bit a pro-inflammatory phenotype associated with
increased number of CLSs and IR in obese subjects.48
Interestingly, also CD11c+ CD163+ ATMs were found to
accumulate in fat of obese individuals and correlate with
high BMI as well as the production of reactive oxygen
species.49
In addition to CD11c+ CD206+ ATMs, it has been
indicated that the population of CD11c+ CD64+ ATMs
also defines pro-inflammatory macrophages.38 Addition-
ally, the population of CD14+ CD16+ CD36high ATMs
has been shown to include highly phagocytic macro-
phages.46 Although a study identified a strong correlation
between CD36 expression on ATMs and metabolic dys-
function,50 CD36 can be found on other cell types, such
as adipocytes and platelets and, thus far, might not be an
optimal candidate marker. Nevertheless, a study has
reported that by using CD163 in addition to CD14,
CD16 and CD36, it was possible to distinguish anti-
inflammatory macrophages (CD14+ CD16 CD36low
CD163+) from pro-inflammatory macrophages
(CD14+ CD16+ CD36high CD163).51 Consistently, the
expression of CD163 has been significantly correlated
with HOMA-IR,52 but the functional relevance of this
marker is unclear.
Properties and functions of ATMs in lean and
obese AT
Although it is not fully resolved what triggers the activa-
tion of ATMs, there is evidence that adipocyte hypertro-
phy and local hypoxia, following energy imbalance,
instigate ATM accumulation,3,43,53 and a switch in the
phenotype of ATMs from an anti-inflammatory state to a
pro-inflammatory state.21 Moreover, not only the accu-
mulation of macrophages, but also an impairment in
macrophage egress has been implicated in obesity-induced
inflammation.54 It has become critical to understand the
mechanisms regulating ATM polarization and how ATM
functions are altered by obesity, as well as the biology of
the macrophage/adipocyte interplay within CLSs; how-
ever, the full spectrum of functions of ATMs are still not
fully clarified despite many advances in the field.
ATM cytokines production
Adipocyte tissue macrophages actively secrete pro- and
anti-inflammatory cytokines.27,55 MMe macrophages have
been considered a significant source of inflammatory
cytokines, whose production can be variably modulated
by NADPH oxidase 2 activity during obesity progres-
sion.17 Within lean AT, anti-inflammatory cytokines
secreted by resident ATMs help maintain insulin sensitiv-
ity by counteracting inflammatory responses. This is
demonstrated by the effect of the treatment of adipocytes
with IL-10 that alleviates tumor necrosis factor (TNF)a-
induced IR.21 Similarly, IL-4, known to polarize anti-
inflammatory macrophages,27 when administrated to
obese mice alleviates inflammatory responses in AT and
improves insulin sensitivity.56 Following adipocyte hyper-
trophy, the secretion of chemoattractants, such as MCP-
1/CCL2, contributes to macrophage recruitment and pro-
duction of pro-inflammatory cytokines, including TNFa,
IL-6 and IL-1b, which act as main effectors of impaired
adipocyte function and inflammatory signals.3,57
Energy metabolism in ATMs
Profiling of intracellular energy metabolism in ATMs has
contributed to further understanding their metabolic
functions in an obese setting. Pro-inflammatory (M1)
macrophages rely on glycolysis for their metabolic
demands.58 Inhibition of glycolysis attenuates the adipo-
cyte release of CCL2 in response to TNF-a or lipopolysac-
charide,59 demonstrating the connection between
metabolism and inflammation. On the contrary, anti-
inflammatory (M2) macrophages rely on oxidative phos-
phorylation (OXPHOS) pathways.60,61 Recent studies have
characterized the metabolic signatures of ATMs in lean
and obese conditions in mice.62 Transcriptome analysis
and extracellular flux measurements of mouse ATMs
revealed that fatty acid oxidation, glycolysis and glu-
taminolysis participate in cytokine release by ATMs in
lean AT62 (Table 2). Glycolysis and OXPHOS pathways
are both activated in ATMs in obesity. However, glycolysis
accounts mostly for the higher cytokine production by
ATMs in obese AT.62 In humans, the relationships of
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macrophage markers with metabolic parameters and
inflammatory biomolecules are not fully clear. However, a
recent study has demonstrated that the regulation of M2-
ATMs in patients with modest obesity may be closely
dependent on mitochondrial biogenesis and OXPHOS
through PGC-1a/b signals.63
Clearance of dead adipocytes
Adipose tissue macrophages are known to participate in
adipocyte death by promoting the clearance of frag-
mented cellular contents via phagocytosis and lysosomal
activation.30,64 Under normal conditions, ATMs phagocy-
tosis of adipocytes debris may be important to maintain
AT homeostasis keeping adipocyte turnover and overall
tissue health. In an obese setting, it is hypothesized that
CLSs ATMs clear dead adipocytes that are generated with
chronic tissue expansion and perhaps in an attempt to
resolve inflammation.65,66 Murine studies based on adipo-
cyte-targeted activation of caspase-8 have demonstrated
that adipocyte death induces the recruitment of macro-
phages.67 Perilipin-negative adipocytes that have under-
gone necrosis-like death, plasma membrane rupture,
endoplasmic reticulum stress and cell debris release have
shown that most of the recruited ATMs specifically
accumulate near dying adipocytes.30,65 Depletion of man-
nose-binding lectin has been linked to increased CLSs
formation and decreased dead adipocyte clearance,68
implicating a role in phagocytic pathways of ATMs. It
has been proposed that these endocytic processes can
overwhelm the metabolic capacity of ATMs to take up
debris and interrupt the normal process of dead cell
clearance, as occurs in foam cell formation and
atherosclerosis,69 leading to maladaptive inflammatory
responses.33,43 Finally, ATMs populations can exert a
complementary role to minimize tissue damage through
tight regulation of phagocytosis and tissue repair.70
Clearance of lipids and lysosomal activity
Because adipocytes are primarily made of large lipid dro-
plets, ATMs play an active role in the clearance of lipid
remains from dead fat cells,30,71 the removal of extracellu-
lar lipids from AT,72 as well as the uptake of triglycerides
and non-esterified fatty acids (FFAs) released by enlarged
insulin-resistant adipocytes.43 These phenomena could
contribute to the prevention of potential damage and
lipotoxicity caused by ectopic accumulation of saturated
FFAs. With increasing adiposity, ATMs store surplus lipid
species, giving rise to a population of the so-called lipid-
laden ATMs,73,74 which have been considered the primary
CLS-forming cells. While these are analogous to
atherosclerotic foam cells, the lipid droplets in ATMs are
primarily laden with FFA and not cholesterol as in
atherosclerotic lesions. Alterations in lipid metabolism in
lipid-laden ATMs have been implicated in pro-inflamma-
tory responses linked to IR.75,76 Studies from Coats
et al.19 observed that FFAs-induced MMe macrophages
Table 2. Properties of ATMs
Mouse Human
Resident Recruited Resident Recruited
Phenotype Anti-inflammatory Pro-inflammatory As in
mouse
Mixed
Function Tissue homeostasis, AT remodeling,
angiogenesis modulation, promotion of pre-
adipocytes survival, efficient efferocytosis of
dead adipocytes, wound healing, resolution of
inflammation, lipid buffering, regulation of
adipocyte lipolysis
Production of inflammatory cytokines and
reactive oxygen species, inefficient dead
adipocyte clearance, adipocyte debris
scavenging, lipid phagocytosis, surplus lipid







IL-10, IL-4, Il-1RA, TGF-b TNF-a, IL-6, IL-1, NO As in
mouse
As in mouse







Promote insulin sensitivity Promote insulin resistance As in
mouse
As in mouse
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are the major subclass responsible for dead adipocyte
clearance and inflammatory cytokine production in obe-
sity. Xu et al.18 demonstrated that the accumulation of
ATMs in obesity and insulin-resistant states correlates
with the induction of lysosomal biogenesis programs in
ATMs. Lysosome biogenesis is found to be tightly cou-
pled to lipid accumulation by ATMs and associated with
increased lipid catabolism. Traditionally, ATMs, that
accumulate intracellularly a large amount of lipids or cell
debris, exert a lysosomal activity through two types of
vesicles that mostly differ based on the pH. Neutral lipid
vesicles fuse with primary lysosome forming an
acidic-ringed secondary lysosome implicated in lipid cata-
bolism pathways.
Exophagy
A hallmark of CLS ATMs is the ability to internalize and
process cell debris and released lipids from dysfunctional
adipocytes.18 However, an exocytosis-based process,
namely exophagy, has been added to the spectrum of func-
tions acquired by ATMs in obesity.77 Exocytosis of lyso-
somes has been previously reported in the context of
macrophage degradation of aggregated LDL in foam cell
formation and atherogenesis.78,79 Based on this process,
CLS ATMs can actively participate in lipid liberation from
the adipocytes and form large moieties in an extracellular
acidic hydrolytic compartment, called lysosomal synapses.
This structure contains lysosomal enzymes, low pH and F-
actin-rich seals, that allow the activity of lysosomal acid
hydrolases.77–79 This process results in extracellular catabo-
lism and subsequent uptake of particles from the suffering
adipocyte.76 It has been hypothesized that exophagy in CLS
ATMs sustains a feed-forward mechanism of inflamma-
tion, linking adipocytes death to pro-inflammatory cyto-
kine release and increased lysosome biogenesis. To this
end, studies by Ying et al.80 have shown that ATMs are also
responsible for the secretion of miRNA-containing extra-
cellular vesicles (EVs), namely Exos. These vesicles are
taken up by adipocytes, where they influence metabolism
by directly affecting cellular insulin signaling. Important
findings have demonstrated that when insulin-sensitive
mice are treated with obese ATM-Exos they develop sys-
temic IR and glucose intolerance. In contrast, treatment of
obese insulin-resistant mice with lean ATM-Exos normal-
izes glucose tolerance and enhances systemic insulin sensi-
tivity. In vitro studies showed that treatment with obese
ATM-Exos decreases insulin-stimulated glucose transport
in adipocytes and myocytes, while lean ATM-Exos
treatment improves insulin action. Upon the screening of
several miRNA-containing EVs, this study proved that
miR-155 contributes to the insulin-resistant, glucose-intol-
erant state conferred by obese ATM-Exos, indicating an
additional mechanism of obesity-induced pro-inflamma-
tory signaling driven by ATM secretory products.
AT remodeling and angiogenesis
Adipose tissue macrophages participate in the physiologi-
cal and pathological remodeling of AT27,66,81 via modulat-
ing new adipocyte formation (adipogenesis),82 as well as
influencing angiogenesis.83 Macrophage depletion using
clodronate liposomes reduces the formation of blood ves-
sels in ATs through the perturbation of angiogenesis.84
Other studies based on hypoxia models have shown that
macrophages recruited into the tip of the gonadal AT
promote angiogenesis during tissue outgrowth.85 These
recruited macrophages are lymphatic vessel endothelial
receptor 1 (LYVE-1)-positive ATMs and participate in tis-
sue remodeling via the secretion of factors, such as matrix
metalloproteinase (MMP)-7, MMP-9 and MMP-12, and
activation of the VEGF-VEGFR2 system to stimulate new
vessel formation.85 Similarly, ATMs isolated from the
human AT secrete MMPs and promote the formation of
endothelial cell tubes in matrigel systems.44 The role of
ATMs in angiogenesis has been linked to the effect of
TNF-a, which can act as an angiogenic factor,86 as well as
to the effect of platelet-derived growth factor, that medi-
ates endothelial cell tube formation and capillary matura-
tion by promoting pericyte recruitment.83 Interestingly, it
has been shown in diet-induced obesity (DIO) models
that a population of osteopontin over-expressing ATMs
could form an adipogenic niche for tissue repair and
remodeling in AT.71 Consistently, osteopontin-deficient
mice fail to form these regenerative adipogenic foci.71
T-cell activation
During the development of obesity, the number of adi-
pose tissue T cells (ATTs) increases as does the CD8+-to-
CD4+ T-cell ratio, whereas the percentage of T regulatory
cells (Tregs) decreases.87 Both CD4+ and CD8+ T cells are
crucial in the recruitment and polarization of ATMs
through cytokines such as interferon (IFN)-c, and the
accumulation of CD8+ T cells into AT precedes the
increase of ATMs.87,88 Several groups have shown that
ATMs are functional antigen-presenting cells that pro-
mote the clonal expansion of antigen-specific T-cell acti-
vation in AT and the generation of IFNc-producing Th1
T cells.89–91 ATMs phagocytose and process antigens for
presentation, express co-stimulatory molecules, and
induce antigen-specific CD4+ T-cell proliferation.90 Both
resident CD11c ATMs and CD11c+ ATMs contribute to
the generation and maintenance of effector/memory ATT
cells and the development of IR with obesity.92
Adipose tissue dendritic cells
Due to shared expression of markers such as CD11b, F4/80
and CD11c,38,93 and Immgen.org, early studies on AT leu-
kocytes did not clearly distinguish and differentiate ATMs
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from ATDCs. This omission may be significant as ATDCs
may be a potent antigen-presenting cell in AT89 crucial in
the priming and differentiation of naive CD4+ T cells.94
The use of the macrophage-specific marker CD64 has
enabled the clarification of the diversity of ATDC
(CD64 CD11c+) and ATM (CD64+CD11c+/) in lean
and obese states. Transcriptional profiling of ATMs and
ATDCs validated their distinct functions and expression
profiles.38,39 Although ATDCs increase quantitatively along
with ATMs in obesity,39,95,96 the contribution of ATDCs to
meta-inflammation and IR remains not completely under-
stood. DIO models have demonstrated that a high-fat diet
regimen determines an increase in ATDCs number in AT
that resemble conventional DCs.39,91 Similarly, an increase
in ATDCs has been positively correlated with high BMI in
humans.89 Studies in mice have demonstrated that the
recruitment of ATDCs during obesity requires the chemo-
kine CCR7 and to a lesser extent CCR2.39 Experiments
with CCR7-deficient mice have attenuated ATDC accumu-
lation and protection against obesity and IR. In addition,
lack of b-catenin in ATDCs is associated with decreased
IL-10 levels and suppressed Treg recruitment to AT lead-
ing to more inflammation.97 Based on certain reports,
human CD11c+CD1c+ and mouse CD11chigh F4/80low
ATDCs have been considered as an inflammatory subtype
of DCs in AT in obesity-associated IR.89 In DIO models, a
population of CDllchighF4/80neg ATDCs has been shown to
be responsible for the induction of both Th1 and Th17
cells, whereas CDllchighF4/80low ATDCs for the differentia-
tion of Th17 cells.98 Induction of a Th17 response via
ATDCs results in the production of the cytokines IL-1b,
IL-6 and IL-23, leading to more inflammation.89,99 Further
research is required to address the true function of ATDCs
and which subsets are involved in obesity-induced inflam-
mation.
Conclusion
Obesity, which has reached pandemic levels, is viewed as
a chronic, low-grade inflammation within the AT as well
as a metabolic disease. Among stromal cells, ATMs play a
key role in the pathogenesis of obesity-driven inflamma-
tion and metabolic complications. Altered environmental
cues and inflammatory phenomena orchestrate macro-
phage polarization patterns, which generally favor tissue
infiltration and acquisition of a metabolic activation state.
Recruited ATMs differ from resident macrophages for
distribution, transcriptomic programming and functional
characterization. In addition to conventional functions,
such as clearing cellular debris and participating in tissue
remodeling and lipid buffering, the release of secretory
products (cytokines and extracellular RNAs) is a critical
way that ATMs apply to regulate other cells as well as
coordinate inflammatory responses. Although it is now
evident that several ATM subsets exist in obese AT,
transcriptional mechanisms, regulatory factors and intra-
cellular pathways that underlie functional differences are
not fully defined. Over the years, another limitation in
the field has been the shared expression of certain cell
markers between ATM and ATDC. Fortunately, recent
data have identified specific markers allowing a better
characterization of ATDC contribution to AT inflamma-
tion. In conclusion, understanding how obesity changes
ATM functions and the molecular mechanism underpin-
ning inflammation of obese AT may lead to novel, thera-
peutic strategies to prevent or treat obesity-induced AT
inflammation. Likely, targeting metabolic capacity and
inflammatory phenotype of ATMs may hold a greater
potential to restore ATM function in obese AT.
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